Biopharmaceuticals
Oncology
FDA
News Release - July 24, 2013
Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma
Source: Verastem
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.